Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(9-10):1487–1493. doi: 10.1038/sj.bjc.6690237

Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or Cytosine arabinoside

M H Neale 1, N Myatt 1, I A Cree 1, C M Kurbacher 2, A J E Foss 3, J L Hungerford 4, P N Plowman 5
PMCID: PMC2362718  PMID: 10188895

Abstract

Treatment of choroidal melanoma by chemotherapy is usually unsuccessful, with response rates of less than 1% reported for dacarbazine (DTIC)-containing regimens which show 20% or more response rates in skin melanoma. Recently, we reported the activity of several cytotoxic agents against primary choroidal melanoma in an ATP-based tumour chemosensitivity assay (ATP-TCA). In this study, we have used the same method to examine the sensitivity of choroidal melanoma to combinations suggested by our earlier study. Tumour material from 36 enucleated eyes was tested against a battery of single agents and combinations which showed some activity in the previous study. The combination of treosulfan with gemcitabine or cytosine arabinoside showed consistent activity in 70% and 86% of cases, respectively. Paclitaxel was also active, particularly in combination with treosulfan (47%) or mitoxantrone (33%). Addition of paclitaxel to the combination of treosulfan + cytosine analogue added little increased sensitivity. For treosulfan + cytosine arabinoside, further sequence and timing experiments showed that simultaneous administration gave the greatest suppression, with minor loss of inhibition if the cytosine analogue was given 24 h after the treosulfan. Administration of cytosine analogue 24 h before treosulfan produced considerably less inhibition at any concentration. While we have so far been unable to study metastatic tumour from choroidal melanoma patients, the combination of treosulfan with gemcitabine or cytosine arabinoside shows activity ex vivo against primary tumour tissue. Clinical trials are in progress. © 1999 Cancer Research Campaign

Keywords: chemosensitivity, melanoma, eye, choroid, ATP, DNA repair, apoptosis, anti-neoplastic agents, combination

Full Text

The Full Text of this article is available as a PDF (121.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert D. M., Niffenegger A. S., Willson J. K. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol. 1992 May-Jun;36(6):429–438. doi: 10.1016/s0039-6257(05)80024-4. [DOI] [PubMed] [Google Scholar]
  2. Albert D. M., Ryan L. M., Borden E. C. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol. 1996 Jan;114(1):107–108. [PubMed] [Google Scholar]
  3. Andreotti P. E., Cree I. A., Kurbacher C. M., Hartmann D. M., Linder D., Harel G., Gleiberman I., Caruso P. A., Ricks S. H., Untch M. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 1995 Nov 15;55(22):5276–5282. [PubMed] [Google Scholar]
  4. Bedikian A. Y., Legha S. S., Mavligit G., Carrasco C. H., Khorana S., Plager C., Papadopoulos N., Benjamin R. S. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995 Nov 1;76(9):1665–1670. doi: 10.1002/1097-0142(19951101)76:9<1665::aid-cncr2820760925>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  5. Cantore M., Fiorentini G., Aitini E., Davitti B., Cavazzini G., Rabbi C., Lusenti A., Bertani M., Morandi C., Benedini V. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori. 1994 Feb 28;80(1):37–39. doi: 10.1177/030089169408000107. [DOI] [PubMed] [Google Scholar]
  6. Chana J. S., Cree I. A., Foss A. J., Hungerford J. L., Wilson G. D. The prognostic significance of c-myc oncogene expression in uveal melanoma. Melanoma Res. 1998 Apr;8(2):139–144. doi: 10.1097/00008390-199804000-00006. [DOI] [PubMed] [Google Scholar]
  7. Cree I. A., Kurbacher C. M. Individualizing chemotherapy for solid tumors--is there any alternative? Anticancer Drugs. 1997 Jul;8(6):541–548. doi: 10.1097/00001813-199707000-00001. [DOI] [PubMed] [Google Scholar]
  8. Cree I. A., Kurbacher C. M., Untch M., Sutherland L. A., Hunter E. M., Subedi A. M., James E. A., Dewar J. A., Preece P. E., Andreotti P. E. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs. 1996 Aug;7(6):630–635. doi: 10.1097/00001813-199608000-00002. [DOI] [PubMed] [Google Scholar]
  9. Foss A. J., Alexander R. A., Jefferies L. W., Hungerford J. L., Harris A. L., Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996 Jul 1;56(13):2900–2903. [PubMed] [Google Scholar]
  10. Foss A. J., Dolin P. J. Trends in eye cancer mortality among adults in the USA and England and Wales. Br J Cancer. 1996 Nov;74(10):1687–1689. doi: 10.1038/bjc.1996.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hunter E. M., Sutherland L. A., Cree I. A., Dewar J. A., Preece P. E., Wood R. A., Linder D., Andreotti P. E. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol. 1993 Jun;19(3):242–249. [PubMed] [Google Scholar]
  12. Iwasaki H., Huang P., Keating M. J., Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood. 1997 Jul 1;90(1):270–278. [PubMed] [Google Scholar]
  13. Kurbacher C. M., Bruckner H. W., Cree I. A., Kurbacher J. A., Wilhelm L., Pöch G., Indefrei D., Mallmann P., Andreotti P. E. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res. 1997 Sep;3(9):1527–1533. [PubMed] [Google Scholar]
  14. Kurbacher C. M., Cree I. A., Bruckner H. W., Brenne U., Kurbacher J. A., Müller K., Ackermann T., Gilster T. J., Wilhelm L. M., Engel H. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs. 1998 Jan;9(1):51–57. doi: 10.1097/00001813-199801000-00006. [DOI] [PubMed] [Google Scholar]
  15. Myatt N., Cree I. A., Kurbacher C. M., Foss A. J., Hungerford J. L., Plowman P. N. The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs. 1997 Sep;8(8):756–762. doi: 10.1097/00001813-199709000-00004. [DOI] [PubMed] [Google Scholar]
  16. Peters G. J., Ruiz van Haperen V. W., Bergman A. M., Veerman G., Smitskamp-Wilms E., van Moorsel C. J., Kuiper C. M., Braakhuis B. J. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol. 1996 Oct;23(5 Suppl 10):16–24. [PubMed] [Google Scholar]
  17. Petty R. D., Sutherland L. A., Hunter E. M., Cree I. A. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin. 1995 Jan-Feb;10(1):29–34. doi: 10.1002/bio.1170100105. [DOI] [PubMed] [Google Scholar]
  18. Plunkett W., Huang P., Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec;6 (Suppl 6):7–13. doi: 10.1097/00001813-199512006-00002. [DOI] [PubMed] [Google Scholar]
  19. Proebstle T. M., Scheibenbogen C., Sterry W., Keilholz U. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma. Eur J Cancer. 1996 Aug;32A(9):1530–1533. doi: 10.1016/0959-8049(96)00135-9. [DOI] [PubMed] [Google Scholar]
  20. Pöch G., Reiffenstein R. J., Baer H. P. Quantitative estimation of potentiation and antagonism by dose ratios corrected for slopes of dose-response curves deviating from one. J Pharmacol Toxicol Methods. 1995 Aug;33(4):197–204. doi: 10.1016/1056-8719(95)00016-b. [DOI] [PubMed] [Google Scholar]
  21. Pöch G., Reiffenstein R. J., Unkelbach H. D. Application of the isobologram technique for the analysis of combined effects with respect to additivity as well as independence. Can J Physiol Pharmacol. 1990 Jun;68(6):682–688. doi: 10.1139/y90-103. [DOI] [PubMed] [Google Scholar]
  22. Raivio I. Uveal melanoma in Finland. An epidemiological, clinical, histological and prognostic study. Acta Ophthalmol Suppl. 1977;(133):1–64. [PubMed] [Google Scholar]
  23. van Moorsel C. J., Veerman G., Bergman A. M., Guechev A., Vermorken J. B., Postmus P. E., Peters G. J. Combination chemotherapy studies with gemcitabine. Semin Oncol. 1997 Apr;24(2 Suppl 7):S7–17-S7-23. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES